心臓マッピングの世界市場予測（2022年～2027年）

世界の心臓マッピングの市場規模は、2020年の7億8,050万1,000米ドルから、2027年には18億2,816万7,000万米ドルに達し、CAGR12.93％で成長すると予測されます。

不健康な生活習慣に起因する心臓にかかわる疾患の増加により、個人はより頻繁に健康診断を受け、適切かつ効果的な心臓の健康診断やEP検査を選択するようになっているため、心臓マッピング製品やデバイスの採用が増加し、予測期間中の市場成長が増大すると考えられます。

当レポートでは、世界の心臓マッピング市場について調査分析し、市場力学、セグメント別の市場分析、競合環境、主要企業などの情報を提供しています。

目次

第1章 イントロダクション

• 市場概要
• COVID-19の影響
• 市場の定義
• 市場セグメンテーション

第2章 調査手法

• 調査データ
• 前提

第3章 エグゼクティブサマリー

• 調査のハイライト

第4章 市場力学

• 市場促進要因
• 市場抑制要因
• ポーターのファイブフォース分析
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 業界における競合情勢
• 業界バリューチェーン分析

第5章 世界の心臓マッピング市場分析：製品別

• イントロダクション
• EPカテーテルアブレーション
• EP実験装置
• EP診断カテーテル
• アクセスデバイス

第6章 世界の心臓マッピング市場分析：適応症別

• イントロダクション
• 心房細動
• 心房粗動
• 房室結節リエントリー性頻脈
• ウォルフ・パーキンソン・ホワイト症候群

第7章 世界の心臓マッピング市場分析：エンドユーザー別

• イントロダクション
• 病院・診療所
• 診断センター

第8章 世界の心臓マッピング市場：地域別

• イントロダクション
• 北米
  • 北米の心臓マッピング市場分析：製品別（2020年～2027年）
  • 北米の心臓マッピング市場分析：適応症別（2020年～2027年）
  • 北米の心臓マッピング市場分析：エンドユーザー別（2020年～2027年）
  • 国別
• 南米
  • 南米の心臓マッピング市場分析：製品別（2020年～2027年）
  • 南米の心臓マッピング市場分析：適応症別（2020年～2027年）
  • 南米の心臓マッピング市場分析：エンドユーザー別（2020年～2027年）
  • 国別
• 欧州
  • 欧州心臓マッピング市場分析：製品別（2020年～2027年）
  • 欧州心臓マッピング市場分析：適応症別（2020年～2027年）
  • 欧州心臓マッピング市場分析：エンドユーザー別（2020年～2027年）
  • 国別
• 中東・アフリカ
  • 中東・アフリカの心臓マッピング市場分析：製品別（2020年～2027年）
  • 中東・アフリカの心臓マッピング市場分析：適応症別（2020年～2027年）
  • 中東・アフリカの心臓マッピング市場分析：エンドユーザー別（2020年～2027年）
  • 国別
• アジア太平洋
  • アジア太平洋の心臓マッピング市場分析：製品別（2020年～2027年）
  • アジア太平洋の心臓マッピング市場分析：適応症別（2020年～2027年）
  • アジア太平洋の心臓マッピング市場分析：エンドユーザー別（2020年～2027年）
  • 国別

第9章 競合環境と分析

• 主要企業と戦略分析
• 新興企業と市場収益性
• 合併・買収・契約・提携
• ベンダーの競争力マトリックス

第10章 企業プロファイル

• Biosense Webster, Inc.
• Medtronic
• Abbott
• BIOTRONIK SE & Co KG
• Acutus Medical
• Baylis Medical Company, Inc.
• Boston Scientific Corporation

The global cardiac mapping market is projected to grow at a CAGR of 12.93% to reach US$1,828.167million by 2027, from US$780.501 million in 2020.

Atrial fibrillation is a serious growing condition that affects the heart, and the major causes include an unhealthy lifestyle that many individuals lead. According to the American Heart Association, about 2.3 million people in the United States alone suffer from atrial fibrillation. This problem significantly increases the risk of having getting a stroke. Moreover, according to the statistical data provided by the NHS (National Health Service), arrhythmia is a problem that is also known as a heart rhythm problem and is approximately faced and experienced by more than 2 million people a year in the UK. The most common types of arrhythmia that people suffer from include atrial fibrillation, in which the heart beats at an irregular and faster than normal pace. One of the reasons that can result in atrial fibrillation is the consumption of high amounts of alcohol or unhealthy eating habits, such as a diet with high levels of fats and cholesterol, which tend to block the arteries. Therefore, these factors lead individuals to go for health checkups more often and opt for proper and effective heart health checkups or EP exams. This leads to an increase in the adoption of cardiac mapping products and devices, thereby augmenting the market growth over the forecast period.

New and E-effective techniques that can successfully treat atrial fibrillation are providing opportunities for the market players they can harness and boost their market position and accelerate market growth.

There are many advancements in and enhanced procures products and techniques coming up to treat the problem of atrial F fibrillation, which is a growing and persistent problem. In March 2020, a clinical trial that uses pulse-field energy to heal patients and poses a novel approach to treating this and achieving more desirable and accurate patient outcomes was published. The trial of this method was conducted by the Heart Rhythm Society (HRS) in 2020 and was also published in Circulation Arrhythmia and Electrophysiology. The test compared the tissue selectivity of the PFA technique over the Radon Frequency ablation (RF) technique. Therefore, groundbreaking tests and findings such as these provide the market players with an opportunity to enhance and upgrade their product lines by adding products catering to this method and contributing e to the market growth over the forecast period.

Cardiac Mapping Industry Product Offerings by Major Market Players in the Cardiac Mapping Market

Furthermore, the interest being shown by the market payers to provide the end-users such as hospitals and diagnostic centres ers with innovative and advanced cardiac mapping products fuels ing the market growth further over the forecast period

Some of the examples of product offerings are as follows:

Biotronik recently announced a collaboration with Acutus Medical to provide a comprehensive service portfolio of electrophysiology, mapping, ablation, and other accessory products to facilitate catheter-based treatment of cardiac arrhythmias. In May 2020, Biotronik announced that they have partnered up with Acutus Medical to provide a comprehensive service portfolio of electrophysiology, mapping, ablation, and some other accessory products to facilitate catheter-based treatment of cardiac arrhythmias. The product is being launched across the regional markets in Europe and Asia. Their product is called the "Acutus AcQMap System. This product is developed with multi-mode mapping capabilities and is a non-contact mapping stem that can facilitate the mapping of unstable and stable rhythms. In addition, it can optimize the treatment of different types of arrhythmia in under 3 minutes.

In October 2019, Baylis Medical, which is considered one of the leading manufacturing companies for cardiology devices to aid the physicians, announced the first use of its new product line called its product, " EPstar Fixed Electrophysiology Catheters.". "The product line includes the "2-French Electrophysiology Catheter", the "6F guiding catheter" for allowing deeper coronary sinus mapping (CS mapping). Furthermore, the EPstar catheters can provide the smallest catheters available for diagnosis in the North American electrophysiology market, allowing physicians to perform the more effective cardiac mapping. In addition, the EPstar catheters can make available the smallest catheters available for the diagnosis available in the North American electrophysiology market, allowing the physicians to carry out more effective cardiac mapping.

The North American region is estimated to hold a significant market share due to the rising geriatric population over the forecast period. The Asia Pacific region is estimated to increase its market share due to the initiatives being taken to improve the medical and healthcare infrastructure of countries such as India.

The North American region is estimated to hold a significant share over the forecast period due to the well-established healthcare industry and the availability of quality healthcare services, coupled with the early adoption of advanced and enhanced medical devices and detection products, which are being made available the market players. In addition, the growing geriatric population and the increased risk posed by heart problems are among other reasons for the rising demand for cardiac mapping in countries such as the US.

The Asia Pacific region is estimated to increase its share over the forecast period due to the initiatives being taken and the investment being made to develop the medical infrastructure in countries such as India to provide better healthcare facilities available to the population.

COVID-19 Impact

The disease outbreak of COVID-19 drives the growth of the cardiac mapping market. Several research studies have been published to provide insight into the downside risk of the pandemic. A research project issued in January 2021 labelled "Cardiac Involvement of COVID-19: A Comprehensive Review" mentioned that COVID-19 can have a substantial impact on patients' cardiovascular systems. COVID-19 fatalities are strongly linked to cardiovascular disease, hypertension, and diabetes. As a result, patients with CVDs must take every precaution against COVID-19, which may necessitate the use of cardiac mapping. Likewise, another research project captioned "Impact of COVID-19 on the Cardiovascular System: A Review of Available Reports" released in October 2020 stated that there is an uptick in high mortality and morbidity suffering from both cardiovascular events and COVID-19. As a result, during treatment, more emphasis should be placed on viral infection-related heart problems. The market for such studies is expected to grow in the future as a result of the need for cardiac mapping as a result of the COVID-19 pandemic.

Recent Developments

January 2022, Medtronic plc, a leading global in healthcare technology, announced an agreement to procure Affera, Inc., a privately-held medical technology-based company in the Boston area. Affera develops and manufactures cardiac mapping and navigation systems.

January 2022, Abbott obtained FDA clearance for its EnSite X EP with EnSite Omnipolar technology. EnSite X EP generates intricate three-dimensional maps of the heart to assist physicians in identifying and treating areas of the heart where unusual rhythms originate.

Segmentation:

• By Product

EP Ablation Catheters

EP Laboratory Devices

EP Diagnostic Catheters

Access Devices

• By Indication

Atrial Fibrillation

Atrial Flutter

Atrioventricular Nodal Reentry Tachycardia

Wolff-Parkinson-White Syndrome

• By End-User

Hospitals and Clinics

Diagnostic Centers

• By Geography

North America

• USA
• Canada
• Mexico

South America

• Brazil
• Argentina
• Others

Europe

• UK
• Germany
• France
• Spain
• Others

Middle East and Africa

• Saudi Arabia
• UAE
• Israel
• Others

Asia Pacific

• Japan
• China
• India
• South Korea
• Thailand
• Indonesia
• Taiwan
• Others

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Overview
• 1.2. COVID-19 Impact
• 1.3. Market Definition
• 1.4. Market Segmentation

2. Research Methodology

• 2.1. Research Data
• 2.2. Assumptions

3. Executive Summary

• 3.1. Research Highlights

4. Market Dynamics

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. Global Cardiac Mapping Market Analysis, By Product

• 5.1. Introduction
• 5.2. EP Ablation Catheters
• 5.3. EP Laboratory Devices
• 5.4. EP Diagnostic Catheters
• 5.5. Access Devices 

6. Global Cardiac Mapping Market Analysis, By Indication

• 6.1. Introduction
• 6.2. Atrial Fibrillation
• 6.3. Atrial Flutter
• 6.4. Atrioventricular Nodal Reentry Tachycardia
• 6.5. Wolff-Parkinson-White Syndrome 

7. Global Cardiac Mapping Market Analysis, By End-User

• 7.1. Introduction
• 7.2. Hospitals and Clinics
• 7.3. Diagnostic Centres

8. Global Cardiac Mapping Market Analysis, by Geography

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. North America Cardiac Mapping Market Analysis, By Product, 2020 to 2027
  • 8.2.2. North America Cardiac Mapping Market Analysis, By Indication, 2020 to 2027
  • 8.2.3. North America Cardiac Mapping Market Analysis, By End-User, 2020 to 2027
  • 8.2.4. By Country
    • 8.2.4.1. United States
    • 8.2.4.2. Canada
    • 8.2.4.3. Mexico
• 8.3. South America
  • 8.3.1. South America Cardiac Mapping Market Analysis, By Product, 2020 to 2027
  • 8.3.2. South America Cardiac Mapping Market Analysis, By Indication, 2020 to 2027
  • 8.3.3. South America Cardiac Mapping Market Analysis, By End-User, 2020 to 2027
  • 8.3.4. 2027
  • 8.3.5. By Country
    • 8.3.5.1. Brazil
    • 8.3.5.2. Argentina
    • 8.3.5.3. Others
• 8.4. Europe
  • 8.4.1. Europe Cardiac Mapping Market Analysis, By Product, 2020 to 2027
  • 8.4.2. Europe Cardiac Mapping Market Analysis, By Indication, 2020 to 2027
  • 8.4.3. Europe Cardiac Mapping Market Analysis, By End-User, 2020 to 2027
  • 8.4.4. By Country
    • 8.4.4.1. UK
    • 8.4.4.2. Germany
    • 8.4.4.3. France
    • 8.4.4.4. Spain
    • 8.4.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Middle East and Africa Cardiac Mapping Market Analysis, By Product, 2020 to 2027
  • 8.5.2. Middle East and Africa Cardiac Mapping Market Analysis, By Indication, 2020 to 2027
  • 8.5.3. Middle East and Africa Cardiac Mapping Market Analysis, By End-User, 2020 to 2027
  • 8.5.4. By Country
    • 8.5.4.1. Saudi Arabia
    • 8.5.4.2. United Arab Emirates
    • 8.5.4.3. Israel
    • 8.5.4.4. Others
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Cardiac Mapping Market Analysis, By Product, 2020 to 2027
  • 8.6.2. Asia Pacific Cardiac Mapping Market Analysis, By Indication, 2020 to 2027
  • 8.6.3. Asia Pacific Cardiac Mapping Market Analysis, By End-User, 2020 to 2027
  • 8.6.4. By Country
    • 8.6.4.1. Japan
    • 8.6.4.2. China
    • 8.6.4.3. India
    • 8.6.4.4. South Korea
    • 8.6.4.5. Thailand
    • 8.6.4.6. Indonesia
    • 8.6.4.7. Taiwan 
    • 8.6.4.8. Others

9. Competitive Environment and Analysis

• 9.1. Major Players and Strategy Analysis
• 9.2. Emerging Players and Market Lucrativeness
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Vendor Competitiveness Matrix

10. Company Profiles 

• 10.1. Biosense Webster, Inc.
• 10.2. Medtronic
• 10.3. Abbott
• 10.4. BIOTRONIK SE & Co KG
• 10.5. Acutus Medical
• 10.6. Baylis Medical Company, Inc.
• 10.7. Boston Scientific Corporation